Forest Ray

UCLA researchers developed an extracellular vesicle-based surface protein assay for early-stage hepatocellular carcinoma.

Revenues rose 9 percent on test service growth, as the company’s net loss swelled to $21.7 million from $1.9 million in Q2 of last year. 

Strong growth in Signatera volumes drove higher revenues, and along with gains in market share, Natera increases its guidance.

The company plans to launch a commercial product sometime after completing its currently ongoing Series A funding round. 

Although it has seemingly tried to do everything, everywhere, all at once with its immune sequencing technology, Adaptive has sharpened its focus. 

The company expects the trial results to bolster sales by increasing physician confidence in the panel.

The Australian company is beginning early commercialization efforts in the United States while exploring wider uses of its assay.  

The firm plans to ramp up US commercialization following the study, while continuing to develop its cell-free RNA diagnostic platform.

Three new studies focusing on the heart, lungs, and kidneys add to a growing body of evidence in support of donor-derived cell-free DNA as an organ health measure.

Despite a report accusing Natera of deceptive billing practices, investment bank Canaccord Genuity maintained a buy position on Natera's stock.